Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Risk genes beyond APOE

Topic: Brain proteins, microglia and lab models

Plain-language summary

This study investigated amyotrophic lateral sclerosis, an adult-onset neurological disorder that leads to the degeneration of motor neurons and involves TDP-43 as a key component of ubiquitinated aggregates. The researchers report eight missense mutations in nine individuals, consisting of six from individuals with sporadic ALS and three from those with familial ALS, alongside a concurring increase of a smaller TDP-43 product. These results further corroborate that TDP-43 is involved in ALS pathogenesis.

What this study adds

Evidence grade: Not rated

Reports mutations in the TARDBP gene in people with sporadic and familial amyotrophic lateral sclerosis. It is not a study of Alzheimer's disease or dementia.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Kabashi, E., Valdmanis, P. N., Dion, P. A., Spiegelman, D., McConkey, B. J., Velde, C. V., et al. (2008). TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics. https://doi.org/10.1038/ng.132

Vancouver

Kabashi E, Valdmanis PN, Dion PA, Spiegelman D, McConkey BJ, Velde CV, et al. TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nature Genetics. 2008. doi:10.1038/ng.132. PMID: 18372902.

BibTeX

@article{kabashi2008-18372902,
  author  = {Kabashi, Edor and Valdmanis, Paul N. and Dion, Patrick A. and Spiegelman, Dan and McConkey, Brendan J. and Velde, Christine Vande and Bouchard, Jean‐Pierre and Lacomblez, Lucette and Pochigaeva, Ksenia and Salachas, François and Pradat, Pierre‐François and Camu, William and Meininger, Vincent and Dupré, Nicolas and Rouleau, Guy Armand},
  title   = {{TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis}},
  journal = {Nature Genetics},
  year    = {2008},
  doi     = {10.1038/ng.132},
  pmid    = {18372902},
  url     = {https://doi.org/10.1038/ng.132}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 15 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.

Key findings

Why it matters

Reports mutations in the TARDBP gene in people with sporadic and familial amyotrophic lateral sclerosis. It is not a study of Alzheimer's disease or dementia.

How this study scored 57/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence left out, no data; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 7 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 0 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 54 of the 95 points it could be judged on, which is 57 of 100. Total 57 of 100.54 of the 95 points we could judge = 57 of 100

Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on strength of evidence, so that was left out: it earned 54 of the 95 points we could judge it on, which is 57 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Nature Genetics)
Journal's citation record 4 / 4 Nature Genetics: journal h-index 776 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence — / 5 No evidence rating recorded — left out of this score
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2008 — within 20 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 7 / 7 Cited 1,553 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 77.7 citations a year over 20 year(s) since 2008
Impact for its field and year 6 / 6 Cited 80.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 3 / 4 Cited 138 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Guy Armand Rouleau: h-index 146 (OpenAlex, whole career)
Institution's track record 1 / 3 Université de Montréal: institution h-index 1,020 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 7 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 18372902)
Free to read 0 / 2 Behind a paywall — scores zero
Points 54 / 95 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 54 of the 95 points we could judge it on is 57 out of 100.
Total 57 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Related studies in Risk genes beyond APOE from nearby years

Also tagged “lewy”

1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk genes beyond APOE

See all studies in Risk genes beyond APOE →